There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
After initiation of androgen deprivation therapy (ADT), most patients progress to
castration-resistant prostate cancer (CRPC) within 2 or 3 yr. In the USA, approximately
67000 men are estimated to have metastatic CRPC.
[1
]
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg,
Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Electronic address: d.tilki@uke.de.
[2
]
Department of Urology, Northwestern Medicine, Chicago, IL, USA.
[3
]
Department of Urology, School of Medicine, University of California-Davis, Sacramento,
CA, USA.